Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company, has announced a definitive securities purchase agreement for an At-the-Market private placement, raising gross proceeds of approximately $1.425 million. The agreement involves the issuance of 136,844 shares of common stock and 93,179 pre-funded warrants, alongside warrants to purchase additional shares at specified prices. The funds will support the announcement of clinical data from Artelo's phase 1 and phase 2 studies, with a portion allocated to purchasing the digital currency SOL and for general corporate purposes. The closing of the offering is contingent upon customary conditions.